Moderna (NASDAQ:MRNA) Insider Shannon Thyme Klinger Sells 3,471 Shares

Moderna, Inc. (NASDAQ:MRNA) insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the transaction, the insider owned 67,468 shares of the company’s stock, valued at $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Moderna Trading Up 0.3%

Moderna stock traded up $0.16 during trading on Monday, hitting $47.60. The company’s stock had a trading volume of 3,926,335 shares, compared to its average volume of 9,185,553. The stock’s fifty day moving average is $49.83 and its 200 day moving average is $43.31. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $59.55. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. The stock has a market capitalization of $18.89 billion, a price-to-earnings ratio of -5.84 and a beta of 1.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The firm had revenue of $389.00 million for the quarter, compared to analysts’ expectations of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. Moderna’s revenue was up 260.2% on a year-over-year basis. During the same period last year, the firm posted ($2.52) EPS. As a group, equities research analysts predict that Moderna, Inc. will post -6.51 EPS for the current year.

Institutional Trading of Moderna

Hedge funds and other institutional investors have recently modified their holdings of the business. MUFG Securities EMEA plc purchased a new stake in shares of Moderna during the second quarter worth about $28,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Moderna during the fourth quarter worth about $31,000. Canton Hathaway LLC purchased a new stake in shares of Moderna during the first quarter worth about $31,000. Ameriflex Group Inc. increased its position in shares of Moderna by 3,775.0% during the third quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock worth $32,000 after acquiring an additional 1,208 shares during the last quarter. Finally, Cromwell Holdings LLC increased its position in shares of Moderna by 39.7% during the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after acquiring an additional 341 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of research analyst reports. Citigroup reissued a “neutral” rating on shares of Moderna in a research report on Monday, February 16th. Barclays boosted their price objective on Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 2nd. Piper Sandler boosted their price objective on Moderna from $63.00 to $69.00 and gave the stock an “overweight” rating in a research note on Monday, February 23rd. Morgan Stanley set a $33.00 price objective on Moderna in a research note on Friday, May 1st. Finally, Evercore set a $35.00 price objective on Moderna in a research note on Tuesday, February 17th. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and five have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $36.60.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.